HIPEC (hyperthermic intraperitoneal chemotherapy) has been primarily successful against peritoneal mesothelioma. One renowned name which definitely needs mention in this respect is Dr. Paul Sugarbaker, a surgical oncologist, whose celebrated work led to the result 75% five year survival rate with the three-step procedure of HIPEC treatment, steps being, cytoreduction with HIPEC, early postoperative intraperitoneal chemotherapy (EPIC), and normothermic intraperitoneal chemotherapy (NIPEC. Prior to this development of cytoreduction with HIPEC, the survival rate was as less as six months of survival after the treatment of peritoneal mesothelioma. His pioneered work of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has been considered as one of the most effective treatments against peritoneal mesothelioma even by the top-badge of HIPEC treatment centers in India.
The first phase of this treatment initiates with cytoreductive surgery. The HIPEC specialists in Delhi focus on eliminating the maximum safe level of tumors in the abdomen with cytoreductive surgery. To enhance the survival rate of the patient and in addition to curb the chances of recurrence of the diseases, the patient is then made to undergo hyperthermic intraperitoneal chemotherapy (HIPEC). In simple terms, the abdomen is bathed with heated chemotherapy in the process of HIPEC. In HIPEC, catheters are inserted inside the abdominal cavity and are likewise connect at the end to the perfusion system. Through this perfusion system, the chemotherapy solution is pumped in and out of the body. Chemotherapy drugs such as doxorubicin are commonly used. This process goes for about an hour while the temperature is regulated for 104 F to kill the cancerous cells. To make sure that all cells are affected by chemotherapy drugs, the abdomen can be massaged. After the infusion is complete, the medical solution is eliminated, and the cavity is cleaned with a saline solution.
The importance of cytoreductive surgery with HIPEC treatment arises from its mechanism of removing those tumors which are even deeply penetrated inside the abdominal cavity, this is why surgeon experts with the scientifically advanced video-assisted thoracoscopic surgery also recommend cytoreductive surgery as a crucial part of the overall HIPEC treatment. In the standard courses, phase I is administered to provide relief to the patient. But the advanced HIPEC cancer treatment more or less follows the three-step protocol of Dr. Sugarbaker’s method.
The cytoreductive surgery with HIPEC surgery in India is followed by Dr. Sugarbaker’s early postoperative intraperitoneal chemotherapy. Early postoperative intraperitoneal chemotherapy includes the administration of chemotherapy drug paclitaxel for its high molecular weight. After the HIPEC, early postoperative intraperitoneal chemotherapy is performed for almost five days under which the patient is made to undergo non-heated intraperitoneal chemotherapy, the chemotherapy drugs reach the most deeply penetrated tumors in the abdominal cavity. The works of Dr. Sugarbaker have also showcased early postoperative intraperitoneal chemotherapy to be beneficial to treat debilitating fluid build-up or ascites in the patients of peritoneal mesothelioma.
For the last step, normothermic intraperitoneal chemotherapy (NIPEC) is provided to the patient. In normothermic intraperitoneal chemotherapy, the patient is treated with adjuvant chemotherapy procedures either through intraperitoneal paclitaxel only or intraperitoneal pemetrexed plus intravenous (IV) cisplatin. These three-step protocols of Dr. Sugarbaker’s approach have been quite helpful in elevating the survival rates of patients suffering from peritoneal mesothelioma.by treating them with a comprehensive HIPEC treatment. All the well-established HIPEC treatment centers have specialized units and experienced surgeons who are assisted by a commendable team to provide this multidisciplinary sort of HIPEC treatment.
The VATS treatment in India is a precision-based effective treatment, their experts have been focused on assessing the risks associated with the HIPEC treatment to bring out solutions which can add to the existing long-term survival rate of the patients who are affected with peritoneal mesothelioma. Wound infections, unexplained bleeding leading to major loss of blood, fever, chills, pain, fatigue, pain and/ or redness at the incision site, and recurrence of the condition are some risks which have to be considered before the HIPEC treatment.